Plain-English translation of NCT07646613 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Migraine research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing ASY202, an inhaled powder medication designed to treat migraine attacks when they happen. You would use a handheld inhaler device to breathe in the medication during a migraine. The study will measure how well the medication works, how safe it is, and how well people tolerate it.
Current migraine treatments don't work for everyone, and doctors are looking for new options that are easy to use and effective. This medication is being tested to see if delivering the treatment through inhalation could be a better way to help people with migraine.
You likely qualify if…
You likely don't qualify if…
The study lasts about 16 weeks total. You will first go through a screening visit, then enter two treatment periods where you'll use either the real medication or a placebo (fake treatment) via a handheld inhaler when you have a migraine attack. There is at least a week-long break between the two treatment periods, and the study ends with a final safety check-up. You and the study team won't know which treatment you're using at any given time, which helps keep the results fair and unbiased.
AI-generated summary from trial data · Jun 19, 2026 · Not medical advice
United States